Minerva Neurosciences, Inc. (NERV) is a clinical-stage biopharmaceutical company focused on developing a portfolio of product candidates targeting central nervous system (CNS) diseases. Since its establishment, the company has devoted its energy towards creating innovative solutions for significant unmet medical needs in the domain of neurology, proving to be a trailblazer in its field.
Headquartered in Waltham, Massachusetts, Minerva Neurosciences is well-known for its significant contribution to neuroscience through advanced therapies and medications. The company's philosophy is centered on utilizing innovative technology and clinical science to bring forth novel treatments that can enhance patients' lives and provide an advantageous alternative to the existing treatments available for neurological disorders.
Under its umbrella, Minerva Neurosciences has several product candidates in various stages of clinical development. These include roluperidone (MIN-101) for the treatment of schizophrenia, seltorexant (MIN-202) in collaboration with Janssen Pharmaceutica, for insomnia disorder and Major Depressive Disorder (MDD), MIN-117 for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease. The advancement and development of these treatments serve as a testament to the company’s focus on enhancing neurological health on a wide scale.
Minerva Neurosciences, Inc. operates under a highly-experienced leadership team with a wealth of knowledge and experience in biopharmaceutical development. With deep-rooted expertise in discovering, developing, and commercializing novel therapeutics, the team is continually driving the company's mission forward to disrupt the healthcare sphere with powerful solutions for CNS conditions.
The company's stock trades on the NASDAQ under the symbol "NERV." Since its initial public offering in 2014, Minerva Neurosciences has grown significantly, with steady growth in its operations, clinical trials, and revenues, reflecting its continual commitment to transforming the landscape of neurology.
By investing in advanced research and focusing on patient needs, Minerva Neurosciences, Inc. continues to pave the way for innovative treatments in the field of neurology. The company is committed to uplifting the standard of care and improving the quality of life for patients coping with CNS diseases. While their path is laden with the typical risks and challenges associated with drug development, the potential to revolutionize the treatment of neurological disorders could have a far-reaching impact on global healthcare.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Minerva Neurosciences reported its third quarter 2026 financial results, highlighting the ongoing confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia, with topline efficacy data expected in H2 2027. The company emphasized roluperidone's position as the only late-stage drug candidate targeting this high-need population and discussed a recent publication advocating for non-dopaminergic mechanisms in schizophrenia treatment. Financially, R&D and G&A expenses increased year-over-year, while the company recorded a significant non-cash gain from changes in fair value of warrant liability, leading to a GAAP net income for the quarter.
Minerva Neurosciences Inc. (NERV) reported a third-quarter profit of $100.7 million. The company also announced a net loss of 19 cents per share, with adjusted losses, excluding non-recurring gains, totaling $1.60 per share. This financial snapshot was generated using data from Zacks Investment Research.
Minerva Neurosciences Director Inderjit Kaul received a stock option for 2,328 shares of common stock, effective November 2, 2026. The options have an exercise price of $2.345 per share and vest in three phases, contingent on time and the achievement of specific clinical trial milestones for the company's roluperidone schizophrenia trial. Kaul's vesting is also tied to his continued service under a consulting agreement.